Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases

  • Christopher M. Rembold
    Requests for reprints should be addressed to Christopher M. Rembold, MD, Cardiovascular Division, University of Virginia Health System, Box 800146, Charlottesville, VA 22908-0146.
    Cardiovascular Division, Department of Internal Medicine, University of Virginia Health System, Charlottesville
    Search for articles by this author
Published:October 25, 2017DOI:



      Multiple-system atrophy is a neurologic disorder characterized by orthostatic hypotension, Parkinsonian signs, and cerebellar signs. Mutations in COQ2, an enzyme involved in coenzyme Q10 synthesis, were recently associated with familial and sporadic cases of multiple-system atrophy. I hypothesized that people with orthostatic hypotension with or without other symptoms of multiple-system atrophy might benefit from oral coenzyme Q10 administration.


      Seven patients with symptomatic orthostatic hypotension were treated in an unrandomized manner with 257 ± 37 mg coenzyme Q10 daily for 10 ± 3 months.


      Before starting coenzyme Q10, patients' systolic blood pressure fell 30 ± 4 mm Hg upon standing from a sitting position. After treatment with coenzyme Q10, their systolic blood pressure decreased 7 ± 5 mm Hg upon standing from a sitting position (P = .007 for change in systolic blood pressure decrease by paired t test).


      These data suggest that orthostatic hypotension could improve with coenzyme Q10 administration and that a randomized clinical trial to test this hypothesis should be begun.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Milliez P.
        • Girerd X.
        • Plouin P.
        • Blatcher J.
        • Safar M.
        • Mourad J.
        Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism.
        J Am Coll Cardiol. 2005; 45: 1243-1248
        • Graham J.G.
        • Oppenheimer D.R.
        Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy.
        J Neurol Neurosurg Psychiatry. 1969; 32: 28-34
        • The Multiple-System Atrophy Research Collaboration
        Mutations in COQ2 in familial and sporadic multiple-system atrophy.
        N Engl J Med. 2014; 369: 233-244
        • Ferrante K.L.
        • Shefner J.
        • Zhang H.
        • et al.
        Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
        Neurology. 2005; 65: 1834-1836